Search results for "Complement"

showing 10 items of 2113 documents

P14ARF: The Absence that Makes the Difference

2020

P14ARF is a tumor suppressor encoded by the CDKN2a locus that is frequently inactivated in human tumors. P14ARF protein quenches oncogene stimuli by inhibiting cell cycle progression and inducing apoptosis. P14ARF functions can be played through interactions with several proteins. However, the majority of its activities are notoriously mediated by the p53 protein. Interestingly, recent studies suggest a new role of p14ARF in the maintenance of chromosome stability. Here, we deepened this new facet of p14ARF which we believe is relevant to its tumor suppressive role in the cell. To this aim, we generated a monoclonal HCT116 cell line expressing the p14ARF cDNA cloned in the piggyback vector …

0301 basic medicinecongenital hereditary and neonatal diseases and abnormalitiesCENP‐Elcsh:QH426-470Cellp14ARFBiologylaw.invention03 medical and health sciences0302 clinical medicinep14arfCDKN2AlawComplementary DNAGeneticsmedicineaneuploidyGenetics (clinical)OncogeneARFP14eye diseasesCell biologySettore BIO/18 - Geneticalcsh:Genetics030104 developmental biologymedicine.anatomical_structureApoptosis030220 oncology & carcinogenesisGSK923295MonoclonalSuppressorCENP-Esense organsGenes
researchProduct

Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

2018

Background Nanoparticle (NP)–based vaccines are attractive immunotherapy tools because of their capability to codeliver antigen and adjuvant to antigen-presenting cells. Their cellular distribution and serum protein interaction ("protein corona") after systemic administration and their effect on the functional properties of NPs is poorly understood. Objectives We analyzed the relevance of the protein corona on cell type–selective uptake of dextran-coated NPs and determined the outcome of vaccination with NPs that codeliver antigen and adjuvant in disease models of allergy. Methods The role of protein corona constituents for cellular binding/uptake of dextran-coated ferrous nanoparticles (DE…

0301 basic medicineendocrine systemOvalbuminCpG OligodeoxynucleotideT-Lymphocytesmedicine.medical_treatmentImmunologyMice Transgenic02 engineering and technologyComplement factor IComplement receptor03 medical and health sciencesImmune systemAntigenLectinsHypersensitivitymedicineAnimalsImmunology and AllergyFerrous CompoundsAntigensAnaphylaxisB-LymphocytesDrug CarriersMice Inbred BALB CVaccinesChemistryDextransImmunotherapyrespiratory system021001 nanoscience & nanotechnologyComplement systemMice Inbred C57BL030104 developmental biologyOligodeoxyribonucleotidesImmunologyNanoparticlesFemaleProtein Corona0210 nano-technologyAdjuvantJournal of Allergy and Clinical Immunology
researchProduct

Cryptotanshinone deregulates unfolded protein response and eukaryotic initiation factor signaling in acute lymphoblastic leukemia cells.

2015

Abstract Background: Unfolded protein responses (UPR) determine cell fate and are recognized as anticancer targets. In a previous research, we reported that cryptotanshinone (CPT) exerted cytotoxic effects toward acute lymphoblastic leukemia cells through mitochondria-mediated apoptosis. Purpose: In the present study, we further investigated the role of UPR in CPT-induced cytotoxicity on acute lymphoblastic leukemia cells by applying tools of pharmacogenomics and bioinformatics. Methods: Gene expression profiling was performed by mRNA microarray hybridization. Potential transcription factor binding motifs were identified in the promoter regions of the deregulated genes by Cistrome software.…

0301 basic medicineendocrine systemXBP1Eukaryotic Initiation Factor-2Pharmaceutical ScienceApoptosisBiology03 medical and health sciencesPhosphatidylinositol 3-KinasesEukaryotic initiation factorCell Line TumorDrug DiscoveryHumansheterocyclic compoundsRNA MessengerEukaryotic Initiation FactorsTranscription factorPharmacologyeIF2ATF4Computational BiologyPromoterPhenanthrenesPrecursor Cell Lymphoblastic Leukemia-LymphomaMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicineCistromePharmacogeneticsEukaryotic Initiation Factor-4AUnfolded protein responseCancer researchUnfolded Protein ResponseMolecular MedicineTranscription Factor CHOPSignal TransductionTranscription FactorsPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Characterization of zolbetuximab in pancreatic cancer models

2018

ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mech…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyCellclaudin 18.2pancreatic cancerlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinePancreatic cancermedicineImmunology and AllergyCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchAntibody-dependent cell-mediated cytotoxicityChemistryimab362medicine.diseasetargeted therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement-dependent cytotoxicity030104 developmental biologymedicine.anatomical_structureOncologyadccCell culturemonoclonal antibody030220 oncology & carcinogenesisCancer researchimmunotherapyzolbetuximablcsh:RC581-607Ex vivoantibody-dependent cellular cytotoxicityOncoImmunology
researchProduct

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

2018

CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in camelids. We previously identified distinct llama nanobodies that recognize three non-overlapping epitopes of the extracellular domain of CD38. Here, we fused these VHH domains to the hinge, CH2, and CH3 domains of human IgG1, yielding highly soluble chimeric llama/human heavy chain antibodies (hcAbs). We analyzed the capacity of these hcAbs to mediate complement-dependent cytotoxicity (CDC) to CD38-expressing human multiple myeloma and Burkitt lymp…

0301 basic medicinelcsh:Immunologic diseases. AllergyRecombinant Fusion ProteinsImmunologyAntineoplastic AgentsEpitope03 medical and health sciencesbiparatopic antibodiesAntigens Neoplasmhemic and lymphatic diseasesCell Line TumorAntibodies BispecificImmunology and AllergyAnimalsHumansCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchHeavy-chain antibodybiologyheavy chain antibodyantibody engineeringChemistryAntibody-Dependent Cell CytotoxicityDaratumumabAntibodies MonoclonalComplement System ProteinsSingle-Domain AntibodiesADP-ribosyl Cyclase 1Complement-dependent cytotoxicityCell biologymultiple myelomananobody030104 developmental biologySingle-domain antibodyCell culturebiology.proteinEpitopes B-LymphocyteImmunotherapyAntibodylcsh:RC581-607Immunoglobulin Heavy ChainsCamelids New WorldCD38Frontiers in Immunology
researchProduct

Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages

2018

Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies (Abs) or Ab-derived molecules directed against TNFα are essential therapeutics. As treatment with several TNFα blockers has been reported to entail a higher risk of infectious diseases such as leishmaniasis, we established an in vitro model based on Leishmania-infected human macrophages, co-cultured with autologous T-cells, for the analysis and comparison of anti-TNFα therapeutics. We demonstrate that neutralization of soluble TNFα (sTNFα) by the anti-TNFα Abs Humira®, Remicade®, and its biosimilar Remsima® negatively affects infection as treatment with these agen…

0301 basic medicinelcsh:Immunologic diseases. AllergyT-LymphocytesImmunologytumor necrosis factor αremicade®03 medical and health sciencesHumansImmunology and AllergyMedicinecomplementleishmaniasisCells CulturedOriginal ResearchLeishmaniahuman macrophagesbiologyTumor Necrosis Factor-alphabusiness.industryEffectorT-cellsMacrophagesAdalimumabAntibodies MonoclonalLeishmaniabiology.organism_classificationAntibodies NeutralizingCoculture TechniquesInfliximabBlockadeComplement systemCytolysis030104 developmental biologyImmunologypolyethylene glycolCertolizumab Pegolbiology.proteinPEGylationTumor necrosis factor alphacimzia®Antibodybusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Manganese Ions Individually Alter the Reverse Transcription Signature of Modified Ribonucleosides

2020

Reverse transcription of RNA templates containing modified ribonucleosides transfers modification-related information as misincorporations, arrest or nucleotide skipping events to the newly synthesized cDNA strand. The frequency and proportion of these events, merged from all sequenced cDNAs, yield a so-called RT signature, characteristic for the respective RNA modification and reverse transcriptase (RT). While known for DNA polymerases in so-called error-prone PCR, testing of four different RTs by replacing Mg2+ with Mn2+ in reaction buffer revealed the immense influence of manganese chloride on derived RT signatures, with arrest rates on m1A positions dropping from 82% down to 24%. Additi…

0301 basic medicinelcsh:QH426-470DNA polymerasechemistry.chemical_elementManganeseSaccharomyces cerevisiaeRT signature[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biology01 natural sciencesArticle03 medical and health sciencesm1ARNA modificationsComplementary DNA[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]GeneticsNucleotidem<sup>1</sup>ABase PairingGenetics (clinical)PolymeraseComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationIonsManganesebiology010405 organic chemistryRNARNA-Directed DNA Polymerase[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyreverse transcriptionMolecular biologyReverse transcriptase0104 chemical scienceslcsh:Genetics030104 developmental biologyTemplatechemistrybiology.proteinRNA[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Ribonucleosidesmanganese chloride
researchProduct

Evaluating ancient Egyptian prescriptions today: Anti-inflammatory activity of Ziziphus spina-christi.

2015

Abstract Background Ziziphus spina-christi (L.) Desf. (Christ's Thorn Jujube) is a wild tree today found in Jordan, Israel, Egypt, and some parts of Africa, which was already in use as a medicinal plant in Ancient Egypt. In ancient Egyptian prescriptions, it was used in remedies against swellings, pain, and heat, and thus should have anti-inflammatory effects. Nowadays, Z. spina-christi, is used in Egypt (by Bedouins, and Nubians), the Arabian Peninsula, Jordan, Iraq, and Morocco against a wide range of illnesses, most of them associated with inflammation. Pharmacological research undertaken to date suggests that it possesses anti-inflammatory, hypoglycemic, hypotensive and anti-microbial e…

0301 basic medicinemedicine.drug_classLeupeptinsIn silicoHerbal MedicineEgypt AncientAnti-Inflammatory AgentsPharmaceutical SciencePlant RootsAnti-inflammatory03 medical and health sciencesCell Line TumorDrug DiscoveryMedicineGallocatechinBioassayHumansElectrophoretic mobility shift assayHistory AncientPharmacologyZiziphus spina-christiInflammationPlants MedicinalbiologyTraditional medicinePlant Stemsbusiness.industryPlant ExtractsTranscription Factor RelAZiziphusZiziphusbiology.organism_classificationMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicineDocking (molecular)SeedsMolecular MedicinebusinessPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Membrane Attack Complex in Myocardial Ischemia/Reperfusion Injury: A Systematic Review for Post Mortem Applications

2020

The complement system has a significant role in myocardial ischemia/reperfusion injury, being responsible for cell lysis and amplification of inflammatory response. In this context, several studies highlight that terminal complement complex C5b-9, also known as the membrane attack complex (MAC), is a significant contributor. The MAC functions were studied by many researchers analyzing the characteristics of its activation in myocardial infarction. Here, a systematic literature review was reported to evaluate the principal features, advantages, and limits (regarding the application) of complement components and MAC in post mortem settings to perform the diagnosis of myocardial ischemia/infar…

0301 basic medicinemedicine.medical_specialtyForensic pathologyClinical BiochemistryInfarctionContext (language use)Reviewischemia/reperfusion injury03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicine030216 legal & forensic medicineMyocardial infarctioncomplement systemlcsh:R5-920business.industryC5b-9schemia/reperfusion injuryforensic pathologymedicine.diseaseComplement systempost mortem investigation030104 developmental biologymyocardial infarctionInclusion and exclusion criteriaCardiologyC5b-9; complement system; forensic pathology; ischemia/reperfusion injury; myocardial infarction; post mortem investigationbusinessComplement membrane attack complexlcsh:Medicine (General)Reperfusion injury
researchProduct

Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

2016

&lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP). &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Mean APTT was significantly shortened in HAE-C1-INH type I (p &lt; 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p &lt; 0.0001) compared to the HP. APTT was shorten…

0301 basic medicinemedicine.medical_specialtyImmunologyAcquired angioedemaGastroenterologyC1-inhibitorDiagnosis Differential03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansImmunology and Allergyheterocyclic compoundsProspective StudiesAngioedemaProspective cohort studyBlood CoagulationBlood coagulation testAngioedemamedicine.diagnostic_testbiologybusiness.industryAngioedemas HereditaryComplement C4General Medicinerespiratory systembacterial infections and mycosesrespiratory tract diseases030104 developmental biologyCoagulationPredictive value of testsAnesthesiaImmunologybiology.proteinPartial Thromboplastin TimeBlood Coagulation Testsmedicine.symptombusinessComplement C1 Inhibitor ProteinBiomarkerscirculatory and respiratory physiologyPartial thromboplastin timeInternational Archives of Allergy and Immunology
researchProduct